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Abstract: Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG monoclonal antibody
directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-
severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four
pivotal Phase III trials: UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent have demon-
strated efficacy and safety in patients with moderate-to-severe plaque psoriasis. This review
highlights important findings from these and other clinical trials that have evaluated risanki-
zumab. In addition, we discuss the mechanism of action, pharmacokinetics/pharmacody-
namics, dosing recommendations, drug interactions, other potential indications, and ongoing
clinical trials.
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Introduction
Psoriasis is a chronic inflammatory skin condition that affects about 3.2% of adults in
the United States.1 It is characterized by excessive inflammation with resultant
hyperproliferation of keratinocytes. Skin findings associated with plaque psoriasis,
the most common form of psoriasis, typically include thick, scaly, erythematous, and
well-circumscribed plaques that are often pruritic and painful. Psoriasis is also
associated with numerous non-dermatologic comorbidities, including psoriatic
arthritis,2 cardiovascular disease,3 diabetes,3 depression,4 and obesity,3 all of which
can negatively impact patients’ quality of life. Psoriasis is mediated by an overactive
Th1 and Th17 response, which induces cytokine dysfunction. Specifically, over-
activation of IL-1, IL-17, TNF-alpha, IL-6, IL-8, IL-12, and IL-23 has been impli-
cated in psoriasis pathogenesis.5 The use of biologic agents to target several of these
inflammatory mediators is now a mainstay in treatment of moderate-to-severe psor-
iasis, which encompasses approximately 20% of psoriasis cases.6
IL-23 is crucial to the pathogenesis of psoriasis, particularly in regard to
differentiation and expansion of Th17 cells. It is primarily produced by dendritic
cells, activated monocytes, and macrophages.7 IL-23 is composed of two subunits:
IL-23p19 and IL-12p40, which combine to form the biologically active version of
the cytokine. Of note, while the p19 subunit is unique to IL-23, the p40 subunit is
also common to IL-12. Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG1
monoclonal antibody that specifically targets the p19 subunit of IL-23. It is FDA
approved for the treatment of moderate-to-severe psoriasis in adults who are
candidates for systemic therapy or phototherapy. This review will provide an over-
view of the available evidence on the efficacy and safety profile of risankizumab for
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the treatment of psoriasis. In addition, it will discuss other
pertinent information for prescribers to be aware of as well
as important ongoing studies that are exploring potential
future indications for risankizumab.
Methods
A literature search of the PubMed and Embase databases
was conducted for the terms “risankizumab” and “psoria-
sis”. Searches were limited to English-language articles
published prior to or on November 2, 2019. Results of
any relevant articles were manually identified by the
authors for review. Duplicate articles were excluded.
Molecular Structure and Mechanism of
Action
Risankizumab is a humanized IgG1 monoclonal antibody
that selectively inhibits the p19 subunit of the heterodi-
meric cytokine IL-23. It is therefore more selective than
certain older biologic agents such as ustekinumab, which
binds to the p40 subunit that is common to both IL-12 and
IL-23. Guselkumab and tildrakizumab are two biologic
agents that also antagonize the p19 subunit of IL-23.
However, they differ from risankizumab in that guselku-
mab is a fully human monoclonal antibody and tildrakizu-
mab is a humanized IgG1 kappa monoclonal antibody.8,9
Dosage
The recommended dose of risankizumab is 150 mg (two
75 mg injections) administered by subcutaneous injection at
week 0, week 4, and subsequent injections every 12 weeks.
There is no weight-based dosing. A Japanese phase II/III trial
(SustaIMM) evaluating the safety and efficacy of risankizu-
mab determined that when compared to a 75 mg dose at
weeks 0 and 4, risankizumab 150 mg dose at weeks 0 and 4
was associated with a faster achievement of PASI 90 and
PASI 100 response rates as well as higher PASI 100 at week
16, while maintaining a similar safety profile.10
Pharmacokinetics
The pharmacokinetic profile of risankizumab has been
derived from seven Phase I-III studies encompassing nearly
1900 patients.11–17 When administered via subcutaneous
injection, the bioavailability (F) of risankizumab is 89%.
Risankizumab exhibits linear and dose-dependent pharma-
cokinetics, as demonstrated by results in both healthy sub-
jects (study doses ranging from 18 mg to 300 mg) and
subjects with psoriasis (study doses ranging from 90 mg
to 180 mg). In these studies, peak plasma concentration
(Cmax) was reached in 3 to 14 days.11 The estimated
Cmax and trough concentration (Ctrough) were approxi-
mately 12 mcg/mL and 2 mcg/mL, respectively.11 At the
recommended dosing regimen of 150 mg administered via
subcutaneous injection at week 0, week 4, and Q12W there-
after, steady-state plasma concentration is achieved by week
16.11 For a typical 90 kg patient with plaque psoriasis,
risankizumab clearance is approximately 0.31 L/day with
an inter-subject variability of 24%.10,12 The estimated
steady-state volume of distribution (VD) is 11.2 L with an
inter-subject variability of 34%.10,11 The terminal-phase
elimination half-life (t½) is approximately 28 days.
10,11 To
our knowledge, studies evaluating the use of risankizumab
in patients with renal and hepatic impairment have not been
conducted thus far. The authors recommend caution when
considering risankizumab use in these patients.
Pharmacodynamics
No formal pharmacodynamic studies using risankizumab
have been conducted thus far.11
Drug Interactions
Khatri et al studied risankizumab’s effect on the in vivo
activity of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and
CYP3A enzymes in patients with moderate-to-severe psor-
iasis (n = 21). Following 12 weeks of dosing with risanki-
zumab 150 mg Q4W, no clinically relevant variations
in vivo activity of CYP1A2, CYP2C9, CYP2C19,
CYP2D6, or CYP3A enzymes were observed.18 These
findings were consistent with those found in other
IL-23p19 inhibitors guselkumab and tildrakizumab.19,20
Immunogenicity
Of subjects treated with risankizumab and evaluated
through 52 weeks, approximately 24% of subjects (263/
1079) taking the recommended dose developed antibodies
to risankizumab.11 Of these subjects, approximately 57%
(14% of all subjects treated with risankizumab) developed
antibodies that were classified as neutralizing.10 Higher
antibody titers seen in approximately 1% of subjects trea-
ted with risankizumab were associated with lower risanki-
zumab concentrations and reduced clinical response.11
Efficacy
The key phase III clinical trials evaluating the efficacy of
risankizumab were: UltIMMa-1 (NCT02684370) (n = 506),
UltIMMa-2 (NCT02684357) (n = 491), IMMhance (n = 507)
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(NCT02672852), and IMMvent (NCT02694523) (n = 605).
Cumulatively, subjects in these studies had a median baseline
PASI (Psoriasis Area and Severity Index) of 17.8 and median
baseline BSA (body surface area) of 20.0%.10 In addition,
38% of study subjects had received prior phototherapy, 48%
had received prior non-biologic systemic therapy, and 42%
had received prior biologic therapy for the treatment of
psoriasis.10 These trials are discussed individually below:
UltIMMa-1 and UltIMMa-2
UltIMMa-1 and UltIMMa-2were replicate, multicenter, dou-
ble-blind, placebo-controlled and active comparator-
controlled, randomized, phase III clinical trials.15 These
studies expanded upon an earlier Phase II trial that demon-
strated superiority of risankizumab when compared to uste-
kinumab up to 12 weeks.13 In both UltIMMa-1 and
UltIMMa-2, patients were randomized (3:1:1) to risankizu-
mab 150 mg, ustekinumab (anti-IL-12/anti-IL-23) 45 mg or
90 mg (weight-based per label), or placebo. At week 16,
patients receiving placebo were switched to risankizumab
150 mg. Subjects received subcutaneous injections at
weeks 0, 4, 16, 28, and 40. The co-primary endpoints were
achieving PASI 90 (achieving at least 90% clearance in
psoriasis compared to baseline) and sPGA 0 or 1 (clear/
almost clear with greater than or equal to 2-point improve-
ment from baseline static Physician Global Assessment
score). Notable secondary endpoints included attainment of
sPGA 0 (clear), PASI 100, DLQI (Dermatology Life Quality
Index) score of 0 or 1 (dermatologic condition having no
impact on quality of life), and PSS (Psoriasis Symptom
Score) of 0. In both studies, risankizumab was superior in
efficacy compared to both placebo and ustekinumab
(p<0.0001 vs placebo and ustekinumab).15 Week 16 and
week 52 PASI 90 and sPGA 0/1 results based on non-
responder imputation from UltIMMa-1 and UltIMMa-2 are
shown in Figures 1 and 2. Additionally, PASI 100, sPGA 0,
DLQI 0 or 1, and PSS 0 response rates at week 52 were also
significantly higher for risankizumab-treated patients than
for ustekinumab-treated patients.15 Regarding risankizumab
durability, PASI 90 response rates were maintained through
week 52. Specifically, 88.4% of patients on continuous risan-
kizumab maintained PASI 90 compared to 73.3% on usteki-
numab (p=0.0009 vs ustekinumab for both studies).15
Risankizumab also demonstrated faster response rates in
patients. PASI 90 responses were significantly higher in
risankizumab-treated patients starting at week 4 than in pla-
cebo-treated patients (p=0.0001; UltIMMa-1 and p<0.0001;
UltIMMa-2) and at week 8 versus ustekinumab-treated
patients (p<0.0001 for both studies).15 These results on clin-
ical improvement mirror histopathologic and cytokine-
induced transcriptomic changes that have demonstrated
improved response to risankizumab in lesional skin com-
pared to ustekinumab.21 Thus, the possibility of earlier clin-
ical improvement with risankizumab may be appealing to
patients who prefer a more rapid response rate when compar-
ing biologic agents.
IMMvent
IMMvent was a multicenter, double-blind, active-com-
parator-controlled, randomized, phase III trial in which
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Figure 1 Week 16 PASI 90 and sPGA 0/1 Reponse Rates in UltIMMA-1 and UltIMMA-2. Data from Gordon et al.15
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patients were randomized (1:1) to either risankizumab or
adalimumab.16 The trial was divided into two portions:
week 0 to 16 and week 16 to 44. In the first 16 weeks,
patients received either risankizumab 150 mg at weeks 0
and 4 or adalimumab 80 mg at week 0 followed by 40 mg
at week 1 and Q2W thereafter. After 16 weeks, patients
initially randomized to adalimumab who achieved PASI 90
remained on adalimumab. Individuals who achieved less
than PASI 50 were switched to risankizumab. Individuals
with PASI 50 or higher but less than PASI 90 were re-
randomized (1:1) to either continue adalimumab or switch
to risankizumab.
Co-primary endpoints PASI 90 and sPGA 0/1 at week 16
(all patients) and PASI 90 and sPGA 0/1 (re-randomized
patients) at week 44 (non-responder imputation) are summar-
ized in Figures 3 and 4, respectively. At week 16,
a significantly higher proportion of patients receiving risan-
kizumab achieved PASI 90 and sPGA 0/1, as well as PASI
75, PASI 100, and sPGA 0 (p<0.0001 for all endpoints).16
Among adalimumab intermediate responders at week 16 (50
≤PASI <90), a larger proportion of individuals who were re-
randomized to risankizumab achieved PASI 90 and PASI 100
at week 44 as compared to those who continued
adalimumab.16 As with UltIMMa-1 and UltIMMa-2, all
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primary and ranked secondary endpoints were achieved in
IMMvent.15,16 Patients who received risankizumab continu-
ously throughout the study generally maintained PASI 90 and
sPGA 0/1 from week 16 to week 44.16 The data for these
particular outcomes was not published, however.
Additionally, as seen when risankizumab was compared to
ustekinumab in UltIMMa-1 and UltIMMa-2, the proportion
of patients achieving PASI 90 in IMMvent was significantly
higher in patients receiving risankizumab when compared to
adalimumab starting at week 8.15,16
IMMhance
IMMhance was a confirmatory, multicenter, double-blind,
placebo-controlled, phase III clinical trial with randomized
withdrawal and re-treatment comparing risankizumab
150 mg with placebo.16 The co-primary efficacy endpoints
were achievement of PASI 90 and sPGA 0/1 at week 16 and
sPGA 0/1 at week 52 (among re-randomized patients). The
trial was split into two portions, part A1 and part B. In part
A1 (weeks 0 to 16), patients were randomized 4:1 to either
risankizumab 150 mg or placebo at weeks 0 and 4. In Part
B (weeks 16 to 52), patients originally randomized to
risankizumab who achieved sPGA 0/1 at week 16 were re-
randomized (1:2) at week 28 to either risankizumab 150 mg
or placebo Q12W. At week 52, PASI 90, PASI 100, and
sPGA 0/1 were significantly greater (p<0.001) in patients
maintained on risankizumab when compared to patients re-
randomized from risankizumab to placebo. At week 52,
87.4% and 85.6% of patients maintained on risankizumab
achieved sPGA 0/1 and PASI 90, respectively. In
comparison, 61.3% and 52.4% of patients switched from
risankizumab to placebo achieved sPGA 0/1 and PASI 90,
respectively.16 Of note, IMMhance provided a timeframe
for the loss of efficacy observed in patients switched off of
risankizumab. Median time to sPGA ≥3 in those who ori-
ginally achieved sPGA 0/1 was significantly different
between the patients re-randomized to continuous risanki-
zumab (not determinable because so few patients lost
response) compared with placebo (288 days) (p<0.001).16
Other Studies
Sawyer et al conducted a systematic review and network
meta-analysis of 77 randomized control trials with a total
of 34,816 patients to compare anti-IL-17 agents to anti-IL
-23 agents.22 Included trials that evaluated risankizumab
were UltIMMa-1, UltIMMa-2, IMMvent, and IMMhance.
When compared to brodalumab (anti-IL-17 receptor), ixe-
kizumab (anti-IL-17A), and guselkumab (anti-IL-23),
risankizumab was not statistically significant in achieving
higher PASI 75, PASI 90, or PASI 100 response rates.22
However, risankizumab, along with brodalumab and ixe-
kizumab, was significantly more efficacious than secuki-
numab, while guselkumab was not.22 Both guselkumab
and risankizumab were more efficacious than tildrakizu-
mab, ustekinumab, all TNF inhibitors, and non-biologic
systemic treatments at inducing all levels of PASI response
rates.22 Overall, all anti-IL-17 agents, guselkumab, and
risankizumab were more efficacious than tildrakizumab,
ustekinumab, adalimumab, and certolizumab, which in
turn were more efficacious than etanercept, apremilast,
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and dimethyl fumarate.22 A separate network meta-
analysis of 27 phase II and phase III randomized control
trials (n = 19,840) that compared short-term efficacy and
safety data of IL-17, IL-12/23, and IL-23 inhibitors found
that risankizumab 150 mg performed better than ustekinu-
mab 45 mg (RR=1.24, 95% CI 1.12–1.37) and brodalumab
140 mg (RR=1.70, 95% CI 1.12–1.44) with regard to
achieving PASI 75 at week 12 or 16.23 Additionally,
risankizumab 150 mg had a lower risk of adverse events
and serious adverse events compared with other IL-23
inhibitors, showing relatively high clinical efficacy and
low treatment risk.23 Of note, this network meta-analysis
only included UltIMMa-1 and UltIMMa-2 and did not
include a comparison of PASI 90 scores because earlier
clinical trials evaluating biologic agents used PASI 75 as
the primary efficacy endpoint. Witjes et al performed
a meta-analysis to assess risankizumab efficacy as com-
pared to adalimumab, independently of IMMvent, which is
the only head-to-head clinical trial comparing risankizu-
mab and adalimumab. The meta-analysis (n=3767)
compared the efficacy of adalimumab in five placebo-
controlled clinical trials24–28 to the efficacy of risankizu-
mab in UltIMMa-1, UltIMMa-2 and IMMhance. As with
IMMvent, risankizumab demonstrated superior efficacy
when compared to the efficacy of adalimumab, as demon-
strated by the head-to-head results in IMMvent.
Safety Profile
The safety profile of risankizumab is comparable to other
biologic agents, although the evaluation of long-term safety
data beyond 52 weeks is ongoing at this time. In UltIMMa-1
and UltIMMa-2, risankizumab was found to have a similar
safety profile to placebo and ustekinumab through week 16,
with no meaningful differences in the following four safety
evaluations: adverse event rates, serious adverse event rates,
severe adverse event rates, and rates of an adverse event
leading to discontinuation of study drug.15 Through week
52, the overall safety profiles and rates of infection were
similar across risankizumab, ustekinumab, and placebo treat-
ment groups, although infections were more frequently
reported in patients receiving risankizumab or ustekinumab
compared with those receiving placebo.15 The rates of ser-
ious infections for the risankizumab group and the placebo
group were ≤0.4%.11,15 Serious infections in the risankizu-
mab group included cellulitis, osteomyelitis, sepsis and
herpes zoster.11,15 IMMhance, which occurred after
UltIMMa-1 and UltIMMa-2, did not identify any new safety
concerns when comparing placebo to risankizumab.16
Risankizumab was also found to have a similar safety profile
to adalimumab in IMMvent.16 In general, themost frequently
reported adverse events (occurring in ≥5% of subjects) in
patients receiving risankizumab were viral upper respiratory
tract infections, upper respiratory tract infections (unspeci-
fied), diarrhea, urinary tract infections, influenza, and
headache14–16 As is consistent with the prescribing practices
of other biologic medications, patients should be evaluated
for tuberculosis prior to initiating therapy and should not
receive live vaccines while being treated with risankizumab.
Preliminary pooled safety data from nine Phase I through III
clinical trials has shown comparable safety profiles in both
short-term and long-term follow-up in moderate-to-severe
psoriasis patients.29
Conclusion
As the number of biologic agents used to treat psoriasis
expands, newer medications provide promise of enhanced
efficacy. In phase III trials conducted thus far, risankizu-
mab has proven to be both efficacious and safe in the
treatment of plaque psoriasis. By specifically targeting
the IL-23p19 subunit and thereby blocking the Th-17/IL-
23 pathway, risankizumab, when compared to other more
non-specific agents, may have a lesser impact on normal
immune function. The head-to-head phase III clinical trials
discussed in this review have demonstrated that risankizu-
mab is superior to ustekinumab and adalimumab in effi-
cacy, including time to visible clinical improvement, and
comparable in its safety profile. Currently, one phase III
clinical trial comparing risankizumab and secukinumab for
subjects with moderate-to-severe plaque psoriasis is
ongoing.30 Another ongoing phase III trial is evaluating
the efficacy of risankizumab compared to methotrexate.31
Long-term efficacy and safety data of risankizumab is
pending.32 In addition, ongoing studies are also examining
the potential for utilization of risankizumab for other indi-
cations. Specifically, these trials are assessing the use of
risankizumab for Crohn’s disease33–36 atopic dermatitis,37
psoriatic arthritis,38,39 erythrodermic and generalized pust-
ular psoriasis,40 and ulcerative colitis.41
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